ESTRELLA IMMUNOPHARMA, INC. Current Federal Tax Expense (Benefit)
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Current Federal Tax Expense (Benefit) of $20.48 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-01.
Discontinued › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2023-08-01
- ESTRELLA IMMUNOPHARMA, INC. current federal tax expense (benefit) for the quarter ending 2023-06-30 was $20.48K.
- ESTRELLA IMMUNOPHARMA, INC. current federal tax expense (benefit) for the quarter ending 2023-03-31 was $41.16K.
- ESTRELLA IMMUNOPHARMA, INC. current federal tax expense (benefit) for the quarter ending 2022-12-31 was $51.18K.
- ESTRELLA IMMUNOPHARMA, INC. current federal tax expense (benefit) for the quarter ending 2022-09-30 was $0.00.
- ESTRELLA IMMUNOPHARMA, INC. current federal tax expense (benefit) for fiscal 2022 was $51.18K.
- ESTRELLA IMMUNOPHARMA, INC. current federal tax expense (benefit) for fiscal 2021 was $0.00.
| Period end | Current Federal Tax Expense (Benefit) 2 month | Current Federal Tax Expense (Benefit) 3 month | Current Federal Tax Expense (Benefit) 6 month | Current Federal Tax Expense (Benefit) 9 month | Current Federal Tax Expense (Benefit) 12 month |
|---|---|---|---|---|---|
| 2023-06-30 | $20.48K 10-Q · filed 2023-08-01 | $61.64K 10-Q · filed 2023-08-01 | $112.82K derived: sum of 3 quarters · filed 2023-08-01 | $112.82K derived: sum of 4 quarters · filed 2023-08-01 | |
| 2023-03-31 | $41.16K 10-Q · filed 2023-05-18 | $92.34K derived: sum of 2 quarters · filed 2023-05-18 | $92.34K derived: sum of 3 quarters · filed 2023-05-18 | $92.34K derived: sum of 4 quarters · filed 2023-05-18 | |
| 2022-12-31 | $51.18K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $51.18K derived: sum of 2 quarters · filed 2023-03-14 | $51.18K derived: sum of 3 quarters · filed 2023-03-14 | $51.18K 10-K · filed 2023-03-14 | |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 4 quarters · filed 2023-05-18 | |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | $0.00 derived: sum of 3 quarters · filed 2023-05-18 | $0.00 derived: sum of 4 quarters · filed 2023-05-18 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-18 | $0.00 derived: sum of 2 quarters · filed 2023-05-18 | $0.00 derived: sum of 3 quarters · filed 2023-05-18 | $0.00 derived: sum of 4 quarters · filed 2023-05-18 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $0.00 derived: sum of 2 quarters · filed 2023-03-14 | $0.00 derived: sum of 3 quarters · filed 2023-03-14 | $0.00 10-K · filed 2023-03-14 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |